Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index; 17 of the 24 sources its claims cite were checked for support.
Abstract
Abstract Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Design Active comparator, new user cohort study. Setting Primary care practices contributing data to the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics Admitted Patient Care and Office for National Statistics Death Registration databases. Participants Patients with type 2 diabetes. Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020. Both cohorts were followed until 29 March 2021. Main outcome measures The primary outcome was suicidality, defined as a composite of suicidal ideation, self-harm, and suicide. Secondary outcomes were each of these events considered separately. Propensity score fine stratification weighted Cox proportional hazards models were fitted to estimate hazard ratios and 95% confidence intervals (CIs) to estimate the average treatment effect among the treated patients. Results The first cohort included 36 082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234 028 DPP-4 inhibitor users (median follow-up 1.7 years). In crude analyses, GLP-1 receptor agonist use was associated with an increased incidence of suicidality compared with DPP-4 inhibitors (crude incidence rates 3.9 v 1.8 per 1000 person years, respectively; hazard ratio 2.08, 95% CI 1.83 to 2.36). This estimate decreased to a null value after confounding factors were accounted for (hazard ratio 1.02, 95% CI 0.85 to 1.23). The second cohort included 32 336 GLP-1 receptor agonist users (median follow-up 1.2 years) and 96 212 SGLT-2 inhibitor users (median follow-up 1.2 years). Similarly, GLP-1 receptor agonist use was associated with an increased risk of suicidality compared with SGLT-2 inhibitors in crude analyses (crude incidence rates 4.3 v 2.7 per 1000 person years; hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12). Similar findings were observed when suicidal ideation, self-harm, and suicide were analysed separately in both cohorts. Conclusions In this large cohort study, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with the use of DPP-4 inhibitors or SGLT-2 inhibitors in patients with type 2 diabetes.
Overview
CoChat Summary
## TL;DR
In this active-comparator, new-user cohort study of patients with type 2 diabetes, GLP-1 receptor agonist use was not associated with a higher risk of suicidality than DPP-4 inhibitors or SGLT-2 inhibitors after confounding adjustment. The crude associations attenuated to null after weighting, and the same pattern held for suicidal ideation, self-harm, and suicide analyzed separately.
## Key findings
- In the GLP-1 receptor agonist vs DPP-4 inhibitor cohort, there were 36,082 GLP-1 receptor agonist users and 234,028 DPP-4 inhibitor users, with median follow-up of 1.3 and 1.7 years, respectively.
- For the primary outcome, crude suicidality rates were 3.9 vs 1.8 per 1,000 person-years and the crude hazard ratio was 2.08 (95% CI 1.83 to 2.36); after weighting, the hazard ratio was 1.02 (0.85 to 1.23).
- In the GLP-1 receptor agonist vs SGLT-2 inhibitor cohort, there were 32,336 GLP-1 receptor agonist users and 96,212 SGLT-2 inhibitor users, with median follow-up of 1.2 years in both groups.
- For the primary outcome in that cohort, crude suicidality rates were 4.3 vs 2.7 per 1,000 person-years and the crude hazard ratio was 1.60 (95% CI 1.37 to 1.87); after weighting, the hazard ratio was 0.91 (0.73 to 1.12).
- Secondary outcomes showed similar null findings after adjustment: vs DPP-4 inhibitors, weighted hazard ratios were 1.00 for suicidal ideation, 0.94 for self-harm, and 0.77 for suicide; vs SGLT-2 inhibitors, they were 0.84 for suicidal ideation, 1.03 for self-harm, and 0.14 for suicide, with wide confidence intervals for suicide.
## Methods
- Active comparator, new user cohort study emulating two target trials: GLP-1 receptor agonists vs DPP-4 inhibitors and GLP-1 receptor agonists vs SGLT-2 inhibitors.
- Data came from UK CPRD GOLD and Aurum, linked to Hospital Episode Statistics Admitted Patient Care and ONS Death Registration databases; patients were followed until outcome, discontinuation/switching, death, end of registration, or 29 March 2021.
- The main analysis used propensity score fine stratification weighting and weighted Cox proportional hazards models to estimate hazard ratios for suicidality, with secondary analyses by individual outcome, subgroup, and sensitivity analyses.
## Limitations
- The paper states that, as with all observational studies, residual confounding is possible; this is noted explicitly in the Discussion.
- The paper states that CPRD does not include prescriptions written by specialists and that exposure misclassification is possible because prescriptions are recorded when written, not necessarily when filled.
- The paper states that restricting self-harm to hospital admission events maximized specificity but could lead to outcome misclassification; it also notes that rare outcomes produced wide confidence intervals in some secondary analyses.
- Evident from the text: the primary analysis excluded self-harm recorded only in primary care, though the authors report a sensitivity analysis expanding the outcome definition yielded nearly identical results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
9 Valid · 1 Not valid · 3 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ONS Death Registration database is a vital statistics database used as the gold standard to identify patients who died from suicide and other causes during follow-up.22 24 25”
§ Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study > Methods > Data sources
What the sources say
- Not matchedcites [22] Medicines & Healthcare products Regulatory Agency. CPRD Linked Data. https://cprd.com/cprd-linked-data.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [24] Office for National Statistics. Deaths. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [25] sourceExperimental — accuracy not yet measured
The Methods (‘Other data sources’) say linked ONS mortality data contain dates and causes of death, and the Results (‘Suicide’) use ONS-confirmed suicides to validate CPRD records. The paper does not show ONS data being used as a gold standard to identify deaths from other causes during follow-up. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Additionally, the rates of suicide and self-harm observed in our study are similar to those observed in the general population in England.31”
§ Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study > Discussion > Strengths and limitations of study
What the sources say
- Could not verifycites [31] sourceExperimental — accuracy not yet measured
Our copy of Sher (2022, QJM) contains no passage mentioning England, nor any suicide or self-harm rate figures for the English general population; searches for 'England general population suicide and self-harm rates', 'self-harm hospital admission rates' and 'deliberate self-harm England cohort' returned only the epidemiology paragraph and reference list. The only comparative epidemiology it offers (Epidemiology of suicidal ideation and behavior in patients with diabetes) reports studies from Canada, Brazil, USA, Quebec, Japan, Sweden and South Korea concluding that suicide ideation, attempts and deaths are INCREASED in diabetes relative to the general population, and a meta-analysis figure of 1.6-fold — it does not address the citing study's own observed rates. Since the claim's specific point (English population benchmarks for suicide and self-harm) is simply not covered, it can be neither confirmed nor refuted from our copy. (LLM, conf=0.62)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clinical trials of GLP-1 receptor agonists have not reported any imbalances in suicidal ideation or self-harm,6 7”
§ Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study > Introduction
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Results report no statistically significant increase in suicidal ideation and behaviors for GLP-1 receptor agonists versus placebo across the included trials. But the claim that clinical trials reported no imbalances is more categorical than that finding: the estimate is imprecise (OR 1.11, 95% CI 0.56–2.19), and the Discussion notes possible underreporting because suicide outcomes were not prespecified. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion reports no imbalance in suicidal ideation between semaglutide and placebo groups in the STEP trials, with one suicide attempt in each group. It also reports a minimally higher rate of suicidal ideation or behavior in liraglutide trial adverse-event reports (0.3% vs 0.1%), so the categorical claim about GLP-1 receptor agonist trials is too broad. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In crude analyses, GLP-1 receptor agonist use was associated with an increased incidence of suicidality compared with DPP-4 inhibitors (crude incidence rates 3.9 v 1.8 per 1000 person years, respectively; hazard ratio 2.08, 95% CI 1.83 to 2.36).”
- Also stated in: § GLP-1 receptor agonists versus DPP-4 inhibitors · plain
“In crude analyses, the use of GLP-1 receptor agonists generated an elevated hazard ratio compared with the use of DPP-4 inhibitors (crude hazard ratio 2.08, 95% confidence interval (CI) 1.83 to 2.36).”
§ Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study > Abstract > Results
plainstates an associationn = 377- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § GLP-1 receptor agonists versus DPP-4 inhibitors · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After weighting, the hazard ratios were close to the null value for suicidal ideation (1.00, 95% CI 0.79 to 1.26) and self-harm (0.94, 0.70 to 1.25); the hazard ratio for suicide was below the null value but with a wide confidence interval (0.77, 0.19 to 3.03).”
§ Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study > Results > GLP-1 receptor agonists versus DPP-4 inhibitors
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
28 more claims
Create a free account to see all 58 claims and every source verdict.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 13
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Rare cases of suicidality have been reported, although one large cohort study did not identify elevated risk after adjustment for other risk factors; the FDA and European Agencies are monitoring potential risk [125].”
The cited source says what the claim attributes to it.
In the citing paper
“Rare cases of suicidality have been reported, although preliminary evaluation using the FDA Adverse Reporting System, post hoc analysis of the STEP clinical trials, and 1 large cohort study have not confirmed any definitive link; the FDA and European Agencies are monitoring potential risk [[53], [54], [55]].”
The cited source says what the claim attributes to it.
In the citing paper
“Nationwide retrospective studies utilizing register data from Sweden and Denmark (2013–2021) and the UK CPRD (2007–2020) have revealed consistent findings, indicating that GLP-1 RAs are not associated with an elevated risk of suicidality relative to DPP-4 or SGLT-2 inhibitors [77,78].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“After adjusting for baseline differences, GLP-1 RA use was not associated with an increased risk of composite suicidality compared to DPP-4 inhibitors (HR: 1.02, 95% CI 0.85, 1.23) or SGLT-2 inhibitors (HR: 0.91, 95% CI 0.73, 1.12).81”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Rare cases of suicidality have been reported, although preliminary evaluation using the FDA Adverse Reporting System, post hoc analysis of the STEP clinical trials, and 1 large cohort study have not confirmed any definitive link; the FDA and European Agencies are monitoring potential risk [53, 54, 55].”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667
Robust causal inference using directed acyclic graphs: the R package ‘dagitty’
Textor, J., van der Zander, B., Gilthorpe, M. S., Liśkiewicz, M., & Ellison, G. T. H. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw341 · Cited by 2,295 · cited 1×
“Data visualisation was done in R version 4.4.0, with the ggplot version 3.5.1 and dagitty version 0.3-4 packages, 39 40 and in Microsoft Excel.”
InfluentialSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum
Wolf, A., Dedman, D., Campbell, J., Booth, H., Lunn, D., Chapman, J., & Myles, P. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz034 · Cited by 861
Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC)
Herbert, A., Wijlaars, L., Zylbersztejn, A., Cromwell, D., & Hardelid, P. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx015 · Cited by 742
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739 · cited 1×
“26 The first cohort was composed of patients who started and continued on either a GLP-1 receptor agonist (dulaglutide, exenatide, liraglutide (except the 3 mg/0.5 mL formulation indicated for weight loss), lixisenatide, semaglutide) or a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin,…”
InfluentialKurth, T., Walker, A. M., Glynn, R. J., Chan, K. A., Gaziano, J. M., Berger, K., & Robins, J. M. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj047 · Cited by 730
Schneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727
Desai, R. J., & Franklin, J. M. (2019) · BMJ · doi:10.1136/bmj.l5657 · Cited by 657 · cited 3×
“33 We achieved this by using multivariable logistic regression to predict the probability of receiving a GLP-1 receptor agonist versus the comparator drug (a DPP-4 inhibitor or SGLT-2 inhibitor) conditional on the previously listed covariates.”
Influential
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Self-citationMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“Rare cases of suicidality have been reported, although one large cohort study did not identify elevated risk after adjustment for other risk factors; the FDA and European Agencies are monitoring potential risk [125].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
Metadata
- Authors
- Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Azoulay, Laurent
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2025-02-26
- Volume
- 388
- Pages
- e080679
- ISSN
- 1756-1833 (ISSN-L)
- PMC
- PMC11863255
- OpenAlex
- W4407947558
- Cited by
- 49
- References
- 40
- Citations by year
- 2026: 29 · 2025: 20
- FWCI
- 33.17
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-04-28)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMJ (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, suicidality, suicidal ideation, self-harm, suicide, DPP-4 inhibitors, SGLT2 inhibitors, antidepressant discontinuation, antidepressant prescribing, adverse drug reactions, antipsychotic prescribing
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Suicide, Cohort Studies, Self-Injurious Behavior, Dipeptidyl-Peptidase IV Inhibitors, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. https://app.cochat.ai/papers/10.1136/bmj-2024-080679
- The paper
- Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L. (2025). Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ. https://doi.org/10.1136/bmj-2024-080679
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.